Literature DB >> 3156740

Studies on 18F-labeled pyrimidines III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice.

K Ishiwata, T Ido, Y Abe, T Matsuzawa, M Murakami.   

Abstract

Metabolic studies of 18F-labeled 5-fluoro-2'-deoxyuridine(FdUrd), 5-fluorouridine(FUrd) and 5-fluorouracil (FUra) were performed in tumor-bearing rats and mice. Also, the usefulness of 18F-FdUrd and 3H-deoxythymidine (dThd) for tumor detection was compared. In the tumor, 2 h after the injection of the 18F-pyrimidines, 3%-11% and 6%-14% of the 18F was present in the nuclear and microsomal fractions, respectively, and 17%-34% and 19%-24% of the 18F was incorporated into the acid-insoluble and nucleotide fractions, respectively. Of the three 18F-pyrimidines, 18F-FUrd demonstrated the highest incorporation rate, while 18F-FUra showed the lowest incorporation rate. The incorporation in the spleen, small intestine, and liver was less than that in the tumor. 3H-dThd and 18F-FdUrd were injected into the same mice. The 3H-dThd was accumulated in the spleen, small intestine, and tumor, and in these three tissues significant amounts of the 3H were incorporated into acid-insoluble materials. However, the clearance of 18F-FdUrd was slow in the tumor but rapid in the spleen and small intestine. In the autoradiograms of the tumor, 18F and 3H showed a slightly different distribution. Both distribution patterns were unchanged when the soluble materials were rinsed out with perchloric acid. For tumor detection, 18F-FdUrd gives the same information as radio-dThd, and further information can be obtained by positron-emission tomography.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156740     DOI: 10.1007/bf00261761

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.

Authors:  J Shani; W Wolf; T Schlesinger; H L Atkins; P R Bradley-Moore; V Casella; J S Fowler; D Greenberg; T Ido; R M Lambrecht; R MacGregor; C Mantescu; R Neirinckx; P Som; A P Wolf; I Wodinsky; K Meaney
Journal:  Int J Nucl Med Biol       Date:  1978-03

2.  Detection of DNA synthesis in intact organisms with positron-emitting (methyl- 11 C)thymidine.

Authors:  D Christman; E J Crawford; M Friedkin; A P Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1972-04       Impact factor: 11.205

3.  Scintigraphy with positron-emitting compounds.--I. Carbon-11 labeled thymidine and thymidylate.

Authors:  E J Crawford; D Christman; H Atkins; M Friedkin; A P Wolf
Journal:  Int J Nucl Med Biol       Date:  1978

4.  Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

Authors:  D V Santi; C S McHenry; H Sommer
Journal:  Biochemistry       Date:  1974-01-29       Impact factor: 3.162

5.  Studies on 18F-labeled pyrimidines. II. Metabolic investigation of 18F-5-fluorouracil, 18F-5-fluoro-2'-deoxyuridine and 18F-5-fluorouridine in rats.

Authors:  K Ishiwata; T Ido; K Kawashima; M Murakami; T Takahashi
Journal:  Eur J Nucl Med       Date:  1984

6.  Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication.

Authors:  S M Larson; P L Weiden; Z Grunbaum; J S Rasey; H G Kaplan; M M Graham; G D Harp; G E Sale; D L Williams
Journal:  J Nucl Med       Date:  1981-10       Impact factor: 10.057

7.  Positron imaging feasibility studies: selective tumor concentration of 3H-thymidine, 3H-uridine, and 14C-2-deoxyglucose.

Authors:  S M Larson; Z Grunbaum; J S Rasey
Journal:  Radiology       Date:  1980-03       Impact factor: 11.105

8.  Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals.

Authors:  Y Abe; H Fukuda; K Ishiwata; S Yoshioka; K Yamada; S Endo; K Kubota; T Sato; T Matsuzawa; T Takahashi; T Ido
Journal:  Eur J Nucl Med       Date:  1983

9.  [3H]thymidine labels less than half of the DNA-synthesizing cells in the mouse tumour, carcinoma NT.

Authors:  E Hamilton; J Dobbin
Journal:  Cell Tissue Kinet       Date:  1982-07

10.  18F-5-Fluorouridine, a new probe for measuring the proliferation of tissue in vivo.

Authors:  E J Crawford; M Friedkin; A P Wolf; J S Fowler; B M Gallagher; R M Lambrecht; R R MacGregor; C Y Shiue; I Wodinsky; A Goldin
Journal:  Adv Enzyme Regul       Date:  1982
View more
  7 in total

1.  Metabolism of 2-deoxy-2-[18F]fluoro-D-glucose: presence of 2-deoxy-2-[18F]fluoro-D-glucose 6-phosphate in plasma of mice, rats, and humans.

Authors:  K Ishiwata; K Kawashima; T Ido
Journal:  Ann Nucl Med       Date:  1987-09       Impact factor: 2.668

Review 2.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

3.  Brain tumor accumulation and plasma pharmacokinetic parameters of 2'-deoxy-5-18F-fluorouridine.

Authors:  K Ishiwata; Y Tsurumi; M Kameyama; K Sato; R Iwata; T Takahashi; T Ido; T Yoshimoto
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

4.  Regional coupling of blood flow and methionine uptake in an experimental tumor assessed with autoradiography.

Authors:  Y Abe; T Matsuzawa; M Itoh; K Ishiwata; T Fujiwara; T Sato; K Yamaguchi; T Ido
Journal:  Eur J Nucl Med       Date:  1988

5.  Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.

Authors:  K Sato; M Kameyama; K Ishiwata; R Katakura; T Yoshimoto
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

6.  Simplified enzymatic synthesis and biodistribution of 11C-S-adenosyl-L-methionine.

Authors:  K Ishiwata; T Ido; H Sato; R Iwata; K Kawashima; K Yanai; S Watanuki; H Ohtomo; K Kogure
Journal:  Eur J Nucl Med       Date:  1986

7.  Clinical application of 18F-FUdR in glioma patients--PET study of nucleic acid metabolism.

Authors:  M Kameyama; K Ishiwata; Y Tsurumi; J Itoh; K Sato; R Katakura; T Yoshimoto; J Hatazawa; M Ito; T Ido
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.